311 related articles for article (PubMed ID: 28695563)
21. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
[TBL] [Abstract][Full Text] [Related]
22. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
Body JJ; von Moos R; Niepel D; Tombal B
BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid in the treatment of metastatic breast cancer.
Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
[TBL] [Abstract][Full Text] [Related]
24. Management of bone metastases in prostate cancer: a review.
Bienz M; Saad F
Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India.
Wadhwa R; Gupta N; Dixit J; Malhotra P; Lakshmi P; Prinja S
JCO Glob Oncol; 2024 Mar; 10():e2300396. PubMed ID: 38452304
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
27. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
[TBL] [Abstract][Full Text] [Related]
28. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
Abdel-Rahman O
Expert Rev Anticancer Ther; 2016 Aug; 16(8):885-91. PubMed ID: 27210216
[TBL] [Abstract][Full Text] [Related]
29. Osteoporosis management in patients with breast cancer: EMAS position statement.
Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
[TBL] [Abstract][Full Text] [Related]
30. Anticancer activity of bisphosphonates in breast cancer.
Gnant M
Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
[TBL] [Abstract][Full Text] [Related]
31. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.
Porta-Sales J; Garzón-Rodríguez C; Llorens-Torromé S; Brunelli C; Pigni A; Caraceni A
Palliat Med; 2017 Jan; 31(1):5-25. PubMed ID: 27006430
[TBL] [Abstract][Full Text] [Related]
32. Bone-modifying agents as adjuvant therapy for early-stage breast cancer.
Figueroa-Magalhães MC; Miller RS
Oncology (Williston Park); 2012 Oct; 26(10):955-62. PubMed ID: 23176008
[TBL] [Abstract][Full Text] [Related]
33. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis.
Jayan A; Raghavendra AS; Bassett R; Barcenas CH
Clin Breast Cancer; 2023 Dec; 23(8):e515-e522. PubMed ID: 37735019
[TBL] [Abstract][Full Text] [Related]
34. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
Hirsh V
Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
[TBL] [Abstract][Full Text] [Related]
35. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Coleman RE
Curr Opin Support Palliat Care; 2012 Sep; 6(3):322-9. PubMed ID: 22801464
[TBL] [Abstract][Full Text] [Related]
37. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
38. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
39. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]